- In recent days, Azra AI and 4DMedical announced a past OEM and reseller partnership that enables 4DMedical to offer Azra AI’s real-time patient-identification platform alongside its quantitative lung imaging technologies, aiming to improve coordinated lung health services for hospital customers.
- This collaboration could make 4DMedical’s offering more comprehensive by pairing its imaging tools with automated patient discovery and care coordination across a range of pulmonary diseases.
- Next, we’ll examine how integrating Azra AI’s patient-identification platform may influence 4DMedical’s growth-focused investment narrative and risk profile.
Uncover the next big thing with 56 elite penny stocks that balance risk and reward.
4DMedical Investment Narrative Recap
To own 4DMedical, you need to believe its lung imaging software can scale from promising technology to a widely adopted clinical tool, despite heavy losses and ongoing cash burn. The Azra AI partnership modestly supports this by making 4DMedical’s solution more “service line” ready, but it does not change the immediate funding risk or the execution risk around commercialising CT:VQ and other products.
Among recent updates, the TGA approval and Australian register listing for CT:VQ stand out, because they sit closest to 4DMedical’s key commercial catalyst of expanding real world scan volumes on existing CT infrastructure. In that context, Azra AI’s patient identification layer may help hospitals actually find and route eligible patients into CT:VQ workflows, but the bigger test remains whether health systems adopt and consistently use these tools at scale.
Yet behind the promise of integrated lung health services, investors should be aware that...
Read the full narrative on 4DMedical (it's free!)
4DMedical's narrative projects A$72.4 million revenue and A$9.1 million earnings by 2029. This requires 131.9% yearly revenue growth and an earnings increase of about A$182 million from -A$172.9 million today.
Uncover how 4DMedical's forecasts yield a A$4.97 fair value, a 34% upside to its current price.
Exploring Other Perspectives
Eight fair value estimates from the Simply Wall St Community span roughly A$0.36 to A$11.11, showing how far apart individual views can be. When you set that against 4DMedical’s ongoing cash burn and need for future capital, it underlines why many investors look at several perspectives before forming a view.
Explore 8 other fair value estimates on 4DMedical - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your 4DMedical research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.
- Our free 4DMedical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 4DMedical's overall financial health at a glance.
Ready For A Different Approach?
Our top stock finds are flying under the radar-for now. Get in early:
- Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com